at Zacks.com (Wed, 12:00PM)
The FDA has approved Novartis' (NVS) Signifor drug to treat sufferers of Cushing's disease who aren't eligible for surgery. Cushing's disease is a rare hormone condition that can cause obesity, skin that bruises easily and excess hair growth. Novartis will have to carry three more analyses of Signifor for high sugar levels in patients' blood, the risks stemming from such levels, and for monitoring the long-term use of the treatment.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 3:46AM)
at Investor's Business Daily (Mon, 8:02AM)
at Zacks.com (Fri, 5:50PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs